Pfizer's coronavirus vaccine could face some headwinds in the near future. The company will enter a period of patent cliffs ...

If you own or are considering buying pharma laggards Pfizer (NYSE: PFE), Bristol Myers Squibb (NYSE: BMY), and Merck (NYSE: ...

Pfizer Inc. (NYSE:PFE) is one of the stocks Jim Cramer was recently asked about. During the episode, a caller inquired if the ...

Pfizer Inc. (NYSE:PFE) is one of the best low volatility large cap stocks to invest in. On November 24, Guggenheim lifted the ...

While Pfizer Inc's (NYSE:PFE) revenue trends remained uneven in the third quarter, the company exhibited "continued cost discipline," according to Goldman Sachs. The Pfizer Analyst: Analyst Asad ...

US pharma giant Pfizer presented results from the Phase III BASIS study evaluating Hympavzi (marstacimab) for adults and adolescents living with hemophilia A or B with inhibitors.

Pfizer's stock has been trading at low levels for a while. Diminished growth and concerns about the future have investors thinking twice about the stock. The company did show signs of progress in its ...

Pfizer Inc. (NYSE: PFE) invites investors and the general public to view and listen to a webcast of a conference call with investment analysts at 8:00 a.m. EST on Tuesday, December 16, 2025. The ...

HYMPAVZI is currently approved in more than 40 countries for the treatment of eligible patients 12 years of age and older living with hemophilia A without factor VIII inhibitors, or hemophilia B ...

Pfizer-funded study finds a next-gen mRNA flu shot works better against current strains — but causes more short-term side effects.